All In Biotech

Drug Trial Radar · NCT03778229

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib (The SAVANNAH Study)

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 367 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

367

Actual

Start

Jan 9, 2019

Primary completion

Aug 23, 2024

Study completion Mar 31, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Hutchison Medipharma Limited
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in participants with epidermal growth factor receptor mutation positive (EGFRm+) and mesenchymal epithelial transition factor positive (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following treatment with osimertinib.

Conditions

  • Carcinoma

Interventions

  • OsimertinibDrug

    Participants will receive oral osimertinib tablets as stated in the arm descripation.

  • SavolitinibDrug

    Participants will receive oral savolitinib tablets as stated in the arm descripation.

  • PlaceboDrug

    Participants will receive oral placebo tablets as stated in the arm descripation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis SetTime frame: Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years
  2. Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis SetTime frame: Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progression until the end of the study, or an approximate maximum of 5.6 years

Locations

90 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California

  • Research Site

    Los Angeles, California

  • Research Site

    Sacramento, California

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Rochester, Minnesota

  • Research Site

    Brooklyn, New York

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Seattle, Washington

  • Research Site

    Barretos, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Goiânia, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Newmarket, Ontario, Canada

  • Research Site

    North York, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Santiago, Chile

  • Research Site

    Santiago, Chile

  • Research Site

    Santiago, Chile

  • Research Site

    Aalborg, Denmark

  • Research Site

    Herlev, Denmark

  • Research Site

    København Ø, Denmark

  • Research Site

    Næstved, Denmark

  • Research Site

    Odense, Denmark

  • Research Site

    Vejle, Denmark

  • Research Site

    Dijon, France

  • Research Site

    Marseille, France

  • Research Site

    Nantes, France

  • Research Site

    Paris, France

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.